Therapeutic effects of tofacitinib on steroid-resistant immune checkpoint inhibitor-associated myocarditis
Background and purpose: Outcomes for cancer patients with steroid-resistant immune checkpoint inhibitor-associated myocarditis (srICIAM) are poor. Intensified immunosuppressive therapies, including tofacitinib, a novel Janus kinase (JAK) inhibitor, may have some therapeutic benefits. However, due to...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Editorial Office of China Oncology
2024-04-01
|
| シリーズ: | Zhongguo aizheng zazhi |
| 主題: | |
| オンライン･アクセス: | http://www.china-oncology.com/thesisDetails#10.19401/j.cnki.1007-3639.2024.04.007 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|